Differences in EBA in the first two days of standard anti-tuberculosis treatment in different geographic regions

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 8, 2014, Pages 1006-1007

  Bark, Charles M ^a   Gitta, Phineas ^a   Johnson, John L ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; DRUG BLOOD LEVEL; DRUG EXPOSURE; GENOTYPE; GEOGRAPHY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LETTER; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; TUBERCULOSIS; UGANDA; BACTERIAL COUNT; DRUG EFFECTS; DRUG MONITORING; FEMALE; MALE; PROCEDURES; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; COLONY COUNT, MICROBIAL; DRUG MONITORING; FEMALE; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 84904565355     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0826     Document Type: Letter

References (12)

1. Bark C M, Gitta P, Ogwang S, et al. Comparison of time to positive and colony counting in an early bactericidal activity study of anti-tuberculosis treatment. Int J Tuberc Lung Dis 2013; 17: 1448-1451.
2. Johnson J L, Ssekasanvu E, Okwera A, et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168: 185-191. (Pubitemid 36920972)
3. Diacon A H, Dawson R, Hanekom M, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother 2010; 54: 3402-3407.
4. Diacon A H, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2011; 15: 949-954.
5. Donald P R, Sirgel F R, Botha F J, et al. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med 1997; 156: 895-900. (Pubitemid 27396432)
6. Sirgel F A, Botha F J, Parkin D P, et al. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J Antimicrob Chemother 1993; 32: 867-875. (Pubitemid 24026587)
7. Jindani A, Dore C J, Mitchison D A. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003; 167: 1348-1354. (Pubitemid 36609718)
8. Parkin D P, Vandenplas S, Botha F J, et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 1997; 155: 1717-1722. (Pubitemid 27216683)
9. Donald P R, Sirgel F A, Venter A, et al. The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid. Clin Infect Dis 2004; 39: 1425-1430. (Pubitemid 39518202)
10. Sirgel F, Venter A, Mitchison D. Sources of variation in studies of the early bactericidal activity of antituberculosis drugs. J Antimicrob Chemother 2001; 47: 177-182. (Pubitemid 32149523)
11. Gagneux S, DeRiemer K, Van T, et al. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2006; 103: 2869-2873.
12. Mac Kenzie W R, Heilig CM, Bozeman L, et al. Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa. PLOS ONE 2011; 6: e18358.